Eris Lifesciences Ltd

Eris Lifesciences has allotted 6,761 equity shares under ESOP on 30 August 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,62,06,793/- (13,62,06,793 equity shares of Re. 1/- each) to Rs. 13,62,13,554/- (13,62,13,554 equity shares of Re. 1/- each).Powered by Capital Market - Live

Eris Lifesciences announced that one of its sterile injectable manufacturing facilities in Ahmedabad has received approval from Anvisa, Brazil's national health regulatory agency. This facility is part of subsidiary Swiss Parenterals that was acquired by Eris in 2024. The approval follows a successful inspection conducted by the regulatory agency in April 2025 of both the injectable facilities of Swiss Parenterals, and the company expects to receive approval for the second facility soon. Both facilities are already EU GMP and PIC/s approved and supply a range of products to several Latin American markets including Mexico, Chile, Argentina and Peru. A company spokesperson said that the Anvisa approval would enable the company to launch its products in Brazil and achieve comprehensive coverage of the Latin American pharma market. Commenting on the development, Amit Bakshi, CMD of Eris said, 'We take this approval as yet another endorsement of our operating and quality standards in life-saving dosage forms like injectables. This approval takes us a step forward in our strategic transformation into a company with increasing focus and leadership in complex injectables and biotechnology. We made major investments to initiate this transformation last year and we are glad to note that we have made significant progress in creating value from these investments with many more exciting developments expected in the quarters to come.'Powered by Capital Market - Live

Eris Lifesciences announced that a manufacturing unit in its Ahmedabad campus has received approval from ANVISA, which is Brazil's national health regulatory agency. This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the Company's manufacturing facilities. The said manufacturing facility has been successfully inspected by various other regulatory agencies earlier in the year.Powered by Capital Market - Live

This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter the Brazilian market, the largest pharmaceutical market in South America. A company spokesperson said that this approval by a stringent regulatory authority like Anvisa is a tangible endorsement of the GMP and quality systems at the company's manufacturing facilities. The said manufacturing facility was also successfully inspected by various other regulatory agencies earlier this year. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company's consolidated net profit rose 41.63% to Rs 117.99 crore on a 7.82% increase in revenue to Rs 771.56 crore in Q1 FY26 as compared with Q1 FY25. The scrip advanced 0.17% to currently trade at Rs 1771.85 on the BSE. Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 41.63% to Rs 117.99 crore in the quarter ended June 2025 as against Rs 83.31 crore during the previous quarter ended June 2024. Sales rose 7.82% to Rs 771.56 crore in the quarter ended June 2025 as against Rs 715.59 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales771.56715.59 8 OPM %35.8634.93 - PBDT231.61191.26 21 PBT161.10115.52 39 NP117.9983.31 42 Powered by Capital Market - Live

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 5 August 2025.Powered by Capital Market - Live

ERIS Lifesciences announced that the 19th Annual General Meeting(AGM) of the company will be held on 25 July 2025.Powered by Capital Market - Live

Profit before tax (PBT) climbed 67.9% YoY to Rs 128.87 crore in Q4 FY25. During the quarter EBITDA stood at Rs 252 crore, up 70% compared with Rs 148 crore posted in same quarter last year. EBITDA margin expanded to 35.8% in Q4 FY25 as against 26.9% in Q4 FY24. Revenue from domestic branded formulation (DBF) business jumped 25% YoY to Rs 602 crore in Q4 FY25. The organic base grew 10% to Rs 529 crore, while revenue from Biocon -2 stood at Rs 73 crore during the period under review. The company reported 22% organic growth in overall insulin revenue to Rs 300 crore despite significant product shortage in RHI throughout the year. On full year basis, the company's consolidated net profit declined 10.3% to Rs 351.84 crore on 44.6% increase in revenue from operations to Rs 2,879.26 crore in FY25 over FY24. On guidance front, for FY26, the company projects an annual revenue addition of Rs 200'300 crore to its overall insulin franchise, beginning October 2025, driven by the insourcing of insulin production at its Bhopal facility. This strategic move is expected to significantly enhance its insulin portfolio. In DBF business, the company anticipates revenue growth of 15% to 21%, translating to revenues in the range of Rs 2,900'3,050 crore. EBITDA for the segment is projected between Rs 1,070 crore and Rs 1,130 crore, with EBITDA margins maintained around 37%. Additionally, the company expects revenues from its Swiss Parentals division to range between Rs 375- 390 crore reflecting a growth of 15'20%. EBITDA for this segment is estimated between Rs 130 crore and Rs 135 crore, with an EBITDA margin of approximately 35%. The company plans to expand Eris-AMD, its new injectable facility, with a capital expenditure of Rs 100- 200 crore in FY26. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live

The key equity indices traded with limited losses in morning trade as investors engaged in mild profit booking despite supportive global cues. The Nifty traded below the 24,900 level. Market participants will closely monitor global trade developments and the ongoing Q4 earnings season, which are likely to influence sentiment in the coming days. Realty shares witnessed buying demand for fifth consecutive trading session. At 10:25 IST, the barometer index, the S&P BSE Sensex, declined 207.05 points or 0.25% to 81,852.37. The Nifty 50 index fell 44.90 points or 0.19% to 24,894.40. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 0.27% and the S&P BSE Small-Cap index shed 0.06%. The market breadth was positive. On the BSE, 1,772 shares rose and 1,729 shares fell. A total of 207 shares were unchanged. Buzzing Index: The Nifty Realty index advanced 1% to 942.55. The index rose 8.8% in the five consecutive trading sessions. DLF (up 5.29%), Raymond (up 4.95%), Sobha (up 0.55%), Prestige Estates Projects (up 0.36%) and Godrej Properties (up 0.09%) advanced. On the other hand, Phoenix Mills (down 1.16%), Macrotech Developers (down 1.01%) and Brigade Enterprises (down 0.91%) declined Stocks in Spotlight: Eris Lifesciences rallied 3.53% after the company reported a 30.29% jump in consolidated net profit to Rs 92.01 crore on 28.38% increase in revenue from operations to Rs 702.60 crore in Q4 FY25 over Q4 FY24. Ashok Leyland added 1.18% after the company's board is scheduled to meet on 23 May to consider the proposal for the issue of bonus shares. Adani Ports & Special Economic Zone (APSEZ) shed 0.18%. The company's board will meet on 23 May to consider issuing non-convertible debentures (NCDs) via a private placement basis.Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 32.11% to Rs 93.84 crore in the quarter ended March 2025 as against Rs 71.03 crore during the previous quarter ended March 2024. Sales rose 28.38% to Rs 702.60 crore in the quarter ended March 2025 as against Rs 547.27 crore during the previous quarter ended March 2024. For the full year,net profit declined 10.26% to Rs 351.84 crore in the year ended March 2025 as against Rs 392.05 crore during the previous year ended March 2024. Sales rose 44.59% to Rs 2879.26 crore in the year ended March 2025 as against Rs 1991.30 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales702.60547.27 28 2879.261991.30 45 OPM %35.9227.12 -35.3333.89 - PBDT206.12130.55 58 804.33613.85 31 PBT128.8776.75 68 488.87431.34 13 NP93.8471.03 32 351.84392.05 -10 Powered by Capital Market - Live